The Journal of Practical Medicine >
Real⁃world analysis of the differences between left and right colorectal cancer based on clinical pathological characteristics and gene testing results
Received date: 2024-10-16
Online published: 2025-01-14
Objective To investigate the heterogeneity between left? and right?sided colorectal cancer （CRC） in terms of clinical pathological features and gene expression， thereby providing a foundation for personalized treatment. Methods A retrospective analysis was conducted on the clinical data， next?generation sequencing （NGS） results， and treatment plans of 186 CRC patients treated at the forth hospital affiliated of guangxi medical university from July 2020 to August 2023. Patients were categorized into left?sided CRC （n = 134） and right?sided CRC （n = 52） based on tumor location. Clinical and pathological characteristics were analyzed using SPSS 24.0 software， and Kaplan?Meier survival curves were generated to compare overall survival （OS） between groups using the Log?rank test. Additionally， this study compared the clinical and pathological features， NGS?based gene mutation profiles， and prognostic differences between left? and right?sided CRC patients. Results In the clinical and pathological characteristics， no significant differences were observed between left? and right?sided CRC patients regarding gender， distant metastasis， ECOG performance status， TNM stage， or levels of carcinoembryonic antigen （CEA） and carbohydrate antigen 19?9 （CA19?9） （P > 0.05）. However， there were significant differences in age （P < 0.05）. In terms of gene mutation characteristics， the mutation frequencies of NRAS， BRAF， and APC genes did not differ significantly between left? and right?sided CRC patients （P > 0.05）. However， right?sided CRC patients exhibited significantly higher mutation frequencies of PIK3CA and SMAD4 genes， as well as a higher prevalence of microsatellite instability （MSI）， compared to left?sided CRC patients （P < 0.05）. Conversely， left?sided CRC patients had significantly higher TP53 mutation frequencies than right?sided CRC patients （P < 0.05）. In prognostic analysis， after a three?year follow?up， no significant difference in OS was observed between the two groups. Conclusions Significant disparities are observed in the clinical pathological features and gene expression profiles between left? and right?sided CRC. These findings indicate that distinct approaches should be adopted in clinical diagnosis and treatment to facilitate personalized and precise care.
Wenying SHANG , Die LONG , Haihui CHEN . Real⁃world analysis of the differences between left and right colorectal cancer based on clinical pathological characteristics and gene testing results[J]. The Journal of Practical Medicine, 2025 , 41(1) : 48 -52 . DOI: 10.3969/j.issn.1006-5725.2025.01.008
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）：209-249. doi:10.3322/caac.21660 |
| 2 | 中华医学会肿瘤学分会， 国家卫生健康委员会医政司.中国结直肠癌诊疗规范（2023版）［J］.协和医学杂志， 2023， 14（4）：706-733. |
| 3 | BUFILL J A. Colorectal cancer： evidence for distinct genetic categories based on proximal or distal tumor location［J］. Ann Intern Med， 1990， 113（10）：779-788. doi:10.7326/0003-4819-113-10-779 |
| 4 | MEZA R， JEON J， RENEHAN A G， et al. Colorectal cancer incidence trends in the United States and United kingdom： evidence of right- to left-sided biological gradients with implications for screening［J］. Cancer Res， 2010， 70（13）：5419-5429. doi:10.1158/0008-5472.can-09-4417 |
| 5 | ARTS F， DE HINGH I， DE WILT J， et al. Differences in outcome between right- and left-sided colon cancer： A population based study［J］. J Clin Oncol， 2013， 31（）：493. doi:10.1200/jco.2013.31.4_suppl.493 |
| 6 | VERHULST J， FERDINANDE L， DEMETTER P， et al. Mucinous subtype as prognostic factor in colorectal cancer： a systematic review and meta-analysis［J］. J Clin Pathol， 2012， 65（5）：381-388. doi:10.1136/jclinpath-2011-200340 |
| 7 | GUINNEY J， DIENSTMANN R， WANG X， et al. The consensus molecular subtypes of colorectal cancer［J］. Nat Med， 2015， 21（11）：1350-1356. |
| 8 | SIEGEL R L， WAGLE N S， CERCEK A， et al. Colorectal cancer statistics， 2023［J］. CA Cancer J Clin， 2023， 73（3）：233-254. doi:10.3322/caac.21772 |
| 9 | UIANJA M B， RISHI M， BEUTLER B D， et al. Colon Cancer Sidedness， Presentation， and Survival at Different Stages［J/OL］. J Oncol， 2019：4315032. doi:10.1155/2019/4315032 |
| 10 | DE BARI O， WANG T Y， LIU M， et al. Estrogen induces two distinct cholesterol crystallization pathways by activating ERα and GPR30 in female mice［J］. J Lipid Res， 2015， 56（9）：1691-1700. doi:10.1194/jlr.m059121 |
| 11 | FRANCESCHI W， BLIGGENSTORFER J， SARODE A L， et al. Primary colorectal tumor location and predictors for metastasis to the brain［J］. Cureus， 2023， 15（5）：e39735. |
| 12 | 孙文燕，邱晶，赖红梅. 左和右半结肠癌患者临床病理特征及预后差异的分析［J］. 当代医学，2021，27（19）：158-161. |
| 13 | BAI W， MA J， LIU Y， et al. Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients［J］. Cancer Med， 2019， 8（5）：2157-2166. doi:10.1002/cam4.2111 |
| 14 | LIU P， WANG Y， LI X. Targeting the untargetable KRAS in cancer therapy［J］. Acta Pharm Sin B， 2019， 9（5）：871-879. doi:10.1016/j.apsb.2019.03.002 |
| 15 | IRAHARA N， BABA Y， NOSHO K， et al. NRAS mutations are rare in colorectal cancer［J］. Diagn Mol Pathol， 2010， 19（3）：157-163. doi:10.1097/pdm.0b013e3181c93fd1 |
| 16 | ZAMAN A， WU W， BIVONA T G. Targeting Oncogenic BRAF： Past， Present， and Future［J/OL］. Cancers（Basel）， 2019， 11（8）：1197. doi:10.3390/cancers11081197 |
| 17 | LEE D W， HAN S W， CHA Y， et al. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer［J］. Cancer， 2017， 123（18）： 3513-3523. doi:10.1002/cncr.30760 |
| 18 | 陈劲松，陈锦旭，张凯. PIK3CA基因在结直肠癌中的意义［J］. 中华普通外科学文献（电子版），2024，18（1）：14-17. |
| 19 | ZHOU J， JI Q， LI Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer： underlying mechanisms and reversal strategies［J］. J Exp Clin Cancer Res， 2021， 40（1）：328. doi:10.1186/s13046-021-02130-2 |
| 20 | SZEGLIN B C， WU C， MARCO M R， et al. A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer［J］. Cancer Rep （Hoboken）， 2022， 5（1）：e1423. doi:10.1002/cnr2.1423 |
| 21 | LOREE J M， PEREIRA A A L， LAM M， et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes ［J］. Clin Cancer Res， 2018， 24（5）：1062-1072. doi:10.1158/1078-0432.ccr-17-2484 |
| 22 | CAO D Z， OU X L， YU T. The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery［J］. Oncol Lett， 2017， 13（5）：3538-3546. doi:10.3892/ol.2017.5929 |
| 23 | JUANES M A. Cytoskeletal Control and Wnt Signaling-APC's Dual Contributions in Stem Cell Division and Colorectal Cancer［J］. Cancers （Basel）， 2020， 12（12）：3811. doi:10.3390/cancers12123811 |
| 24 | MORISHIMA T， OKAWA S， KOYAMA S， et al. Between-hospital variations in 3-year survival among patients with newly diagnosed gastric， colorectal， and lung cancer［J］. Sci Rep， 2022， 12（1）：7134. doi:10.1038/s41598-022-11225-5 |
| 25 | WEISS J M， PFAU P R， O'CONNOR E S， et al. Mortality by stage for right- versus left-sided colon cancer： analysis of surveillance， epidemiology， and end results-Medicare data［J］. J Clin Oncol， 2011， 29（33）：4401-4409. doi:10.1200/jco.2011.36.4414 |
| 26 | ZAKI T A， LIANG P S， MAY F P， et al. Racial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival［J］. Clin Gastroenterol Hepatol， 2023， 21（2）：497-506. doi:10.1016/j.cgh.2022.05.035 |
/
| 〈 |
|
〉 |